CTSS and cancer: When not tightly controlled however, aberrant CTSS expression and activity have been demonstrated in a variety of pathologies, ranging from cardiovascular disease to respiratory conditions and cancer, marking it out as both a biomarker and potential therapeutic target (Smyth et al., 2022).